{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:11:27Z","timestamp":1786979487856,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur. J. Drug Metabol. Pharmacokinet."],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/bf03191157","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T07:26:42Z","timestamp":1281511602000},"page":"93-99","source":"Crossref","is-referenced-by-count":35,"title":["Lamotrigine and valproate pharmacokinetics interactions in epileptic patients"],"prefix":"10.1007","volume":"34","author":[{"given":"Mladena","family":"Lalic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Cvejic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovan","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Bozic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Golocorbin-Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF03191157_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/clpt.1987.193","volume":"42","author":"A.F. Cohen","year":"1987","unstructured":"Cohen A.F., Land G.S., Breimer D.D., Yuen W.C., et al (1987): Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin. Pharmacol. Ther., 42, 535\u2013541.","journal-title":"Clin. Pharmacol. Ther."},{"key":"BF03191157_CR2","unstructured":"Sweetman S (2007): Martindale: The complete drug reference. London, United Kingdom."},{"key":"BF03191157_CR3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0090-9556(25)06536-5","volume":"23","author":"M.D. Green","year":"1995","unstructured":"Green M.D., Bishop W.P., Tephley T.R. (1995): Expressed human UGT 1,4 protein catalyzes the formation of quaternary ammonium-linked glucuronides. Drug Metab. Disp., 23, 299\u2013302.","journal-title":"Drug Metab. Disp."},{"key":"BF03191157_CR4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/00912709922007949","volume":"39","author":"H.G. Thaddeus","year":"1999","unstructured":"Thaddeus H.G., Fiedler-Kelly J., Cox E., et al (1999): Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. J. Clin. Pharmacol., 39, 373\u2013384.","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"BF03191157_CR5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","volume":"43","author":"N.P. Patasalos","year":"2002","unstructured":"Patasalos N.P., Froscher W., Pisani F., et al (2002). The importance of drug interactions in epilepsy therapy. Epilepsia, 43 (4), 365\u2013385.","journal-title":"Epilepsia"},{"key":"BF03191157_CR6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1528-1157.1986.tb03536.x","volume":"27","author":"CD. Binnie","year":"1986","unstructured":"Binnie CD., Van Emde Boas W., Kasteleijn Nolste Trenite D.G., et al (1986). Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia, 27, 248\u201354.","journal-title":"Epilepsia"},{"key":"BF03191157_CR7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","volume":"26","author":"M.J. Brodie","year":"1997","unstructured":"Brodie M.J., Yuen A.W.C., and the 105 Study Group (1997): Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res., 26,423\u201322.","journal-title":"Epilepsy Res."},{"key":"BF03191157_CR8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1600-0404.1995.tb00434.x","volume":"91","author":"CD. Ferrie","year":"1995","unstructured":"Ferrie CD., Robinson R.O., Knott C, Panayiotopoulos CP. (1995): Lamotrigine as an add-on drug in typical absance seizures. Act. Neurol. Scand., 91, 200\u201312.","journal-title":"Act. Neurol. Scand."},{"key":"BF03191157_CR9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1059-1311(05)80208-0","volume":"3","author":"CD. Ferrie","year":"1994","unstructured":"Ferrie CD., Panayiotopoulos CP. (1994) Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure, 3, 157\u201359.","journal-title":"Seizure"},{"key":"BF03191157_CR10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jpba.2005.02.045","volume":"39","author":"K.M. Patil","year":"2005","unstructured":"Patil K.M., Bodhankar S.L. (2005): Simultaneous determination of lamotrigine, phenobarbitone, carbamazepine and phenytoin in human serum by high-performance liquid chromatography. J. Pharmaceut. Biomed., 39, 181\u2013186.","journal-title":"J. Pharmaceut. Biomed."},{"key":"BF03191157_CR11","series-title":"WHO Technical Report Series","volume-title":"Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee","author":"WHO.","year":"1995","unstructured":"WHO. (1995): Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization."},{"key":"BF03191157_CR12","unstructured":"WHO expert consultation. (2004): Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. The Lancet, 157\u2013163."},{"key":"BF03191157_CR13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007691-199610000-00001","volume":"18","author":"T.W. May","year":"1996","unstructured":"May T.W., Rambeck B., Jurgus U. (1996): Serum concentration of lamotrigine in epileptic patients: the influence of dose and co medication. Ther. Drug Monit., 18, 523\u2013531.","journal-title":"Ther. Drug Monit."},{"key":"BF03191157_CR14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/00007691-199904000-00008","volume":"21","author":"J.A. Armijo","year":"1999","unstructured":"Armijo J.A., Bravo J., Cuadrado A., et al. (1999): Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther. Drug. Monit., 21, 182\u2013190.","journal-title":"Ther. Drug. Monit."},{"key":"BF03191157_CR15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2125.1998.00835.x","volume":"46","author":"G.M. Raymond","year":"1998","unstructured":"Raymond G.M., Andrew B.B., Annie L.H., et al. (1998): Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of routine service. Br. Clin. Pharmacol., 46, 547\u2013551.","journal-title":"Br. Clin. Pharmacol."},{"key":"BF03191157_CR16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(95)90581-2","volume":"345","author":"M.J. Brodie","year":"1995","unstructured":"Brodie M.J., Rochens A., Yuen A.W.C. (1995): Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet, 345, 476\u2013479.","journal-title":"Lancet"},{"key":"BF03191157_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2003.09.008","volume":"57","author":"B.E. Gidal","year":"2003","unstructured":"Gidal B.E., Sheth R., Parnell J., et al. (2003): Evaluation of VPA dose and concentration effect in lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy. Epilepsy Res., 57, 85\u201393.","journal-title":"Epilepsy Res."},{"key":"BF03191157_CR18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0920-1211(00)00160-1","volume":"42","author":"B.E. Gidal","year":"2000","unstructured":"Gidal B.E., Anderson G.D., Rutecki P.R., et al. (2000): Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res., 42, 23\u201331.","journal-title":"Epilepsy Res."},{"key":"BF03191157_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0920-1211(02)00033-5","volume":"49","author":"G.D. Anderson","year":"2002","unstructured":"Anderson G.D., Gidal B.E., Messenheimer J.A., et al. (2002): Time course of lamotrigine de-induction: impact step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res., 49,211\u2013217.","journal-title":"Epilepsy Res."},{"key":"BF03191157_CR20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/00007691-199712000-00003","volume":"19","author":"D. Batino","year":"1997","unstructured":"Batino D., Croci D., Granata T., Estienne M., et al. (1997): Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. Ther. Drug Monit., 19, 620\u2013627.","journal-title":"Ther. Drug Monit."},{"key":"BF03191157_CR21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00007691-199706000-00002","volume":"19","author":"A. Bartoli","year":"1997","unstructured":"Bartoli A., Guerini R., Belmote A., et al. (1997): The influence of dosage, age, and co-medication on steady state plasma concentrations in epileptic children: a prospective study with preliminary assessment of correlation with clinical response. Ther. Drug Monit., 19, 252\u2013260.","journal-title":"Ther. Drug Monit."},{"key":"BF03191157_CR22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0090-9556(25)06536-5","volume":"23","author":"M.D. Green","year":"1995","unstructured":"Green M.D., Bishop W.P., Theley T.R. (1995): Expressed human UGT1, 4-protein catalysis the formation of quaternary ammonium linked glucuronids. Drug Metab. Disp., 23, 299\u2013302.","journal-title":"Drug Metab. Disp."},{"key":"BF03191157_CR23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/cc3742","volume":"9","author":"E.R. Philippe","year":"2005","unstructured":"Philippe E.R., Penaloza A., Zahir S., et al. (2005): Carnitine in the treatment of valproic acid-induced toxicity- what is the evidence? Critical Care, 9,431\u2013440.","journal-title":"Critical Care"},{"key":"BF03191157_CR24","first-page":"155","volume":"10","author":"R. Gugker","year":"1980","unstructured":"Gugker R., von Ubruh G.E. (1980): Clinical pharmacokinetic of valproic acid. Clin. Pharmacokinet., 10, 155\u2013163.","journal-title":"Clin. Pharmacokinet."},{"key":"BF03191157_CR25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","volume":"113","author":"H. Stefab","year":"2007","unstructured":"Stefab H., Feuerstein T.J. (2007): Novel anticonvulsant drugs. Pharm, and Therapeutics, 113, 165\u2013183.","journal-title":"Pharm, and Therapeutics"},{"key":"BF03191157_CR26","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","volume":"2","author":"N.P. Ptsalos","year":"2003","unstructured":"Ptsalos N.P., Perucca E. (2003): Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet, 2, 347\u2013355.","journal-title":"Lancet"},{"issue":"1","key":"BF03191157_CR27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1124\/jpet.106.102491","volume":"320","author":"S. Baltes","year":"2007","unstructured":"Baltes S., Fedrowitz M., Tortos CL., et al. (2007): Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J. Pharmacol. Exp. Ther., 320(1), 331\u2013343.","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BF03191157_CR28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0304-3940(02)00423-8","volume":"327","author":"H. Potschka","year":"2002","unstructured":"Potschka H., Fedrowitz M., Loscher W.P. (2002): Glycoprotein-mediated efflux of ph\u00e9nobarbital, lamotrigine, and felbamate at blood brain barrier: evidence from mycrodialysis experiments in rats. Neurosci. Lett., 327, 173\u2013176.","journal-title":"Neurosci. Lett."},{"key":"BF03191157_CR29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2125.1992.tb04079.x","volume":"33","author":"A.W.C Yuen","year":"1992","unstructured":"Yuen A.W.C, Land G., Weatherlely B.C., et al. (1992): Sodium valproate acutely inhibits lamotrigine metabolism. Br. J. Clin. Pharmacol., 33, 511\u2013513.","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"suppl. 9","key":"BF03191157_CR30","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1528-1157.1999.tb02088.x","volume":"40","author":"E. Perucca","year":"1999","unstructured":"Perucca E. (1999): The clinical pharmacokinetics of the new antiepileptic Drugs. Epilepsia, 40 (suppl. 9), S7-S13.","journal-title":"Epilepsia"},{"key":"BF03191157_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1059-1311(96)80063-X","volume":"5","author":"G. Schapel","year":"1996","unstructured":"Schapel G., Black A., Lam E., et al. (1996): Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure, 5, 51\u201356.","journal-title":"Seizure"},{"key":"BF03191157_CR32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","volume":"43","author":"Z. Hussein","year":"1997","unstructured":"Hussein Z., Posner J. (1997): Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br. J. Clin. Pharmacol., 43,457\u2013465.","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03191157.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03191157\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03191157","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:09:51Z","timestamp":1740348591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03191157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["BF03191157"],"URL":"https:\/\/doi.org\/10.1007\/bf03191157","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}